Iantrek reports that it has raised $42 million in a Series C financing round. The company says it will use these funds to support the commercial launch of AlloFlo Uveo, and to advance development across the company’s broader pipeline.

AlloFlo Uveo is the first homologous, bioconforming solution engineered specifically to enhance the uveoscleral outflow pathway by reinforcing a controlled cyclodialysis cleft with an allogeneic biotissue scaffold. The procedure is performed with the AlloSert Uveo system. More than 3,000 procedures have been performed to date, with peer-reviewed data demonstrating meaningful intraocular pressure reduction and reduced need for medications, the company reports. Iantrek’s pipeline also includes CanaloFlo, CycloPen, and C.Rex, which offer novel microinterventional and biointerventional approaches to improve surgical precision and expand treatment options for glaucoma. GP